相关实验视频
Updated: Jan 16, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.6K
关于他类药物对氧沙利普拉丁诱导的外周神经病变的有效性:一个多中心回顾性观察性研究
Kenshi Takechi1, Takehiro Kawashiri2, Keisuke Mine2
1Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University, Matsuyama, Japan.
Clinical and translational science
|September 29, 2025
概括
在结肠直肠癌患者中,他类药物可以预防氧沙胺诱导的外周神经病变 (OIPN). 这项研究没有发现OIPN的整体保护,但在使用他类药物的CRC患者中发现了显著的益处.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛津产生的外围神经病变 (OIPN) 显著影响患者的生活质量.
- 众所周知降低胆固醇的他类药物具有性作用,包括潜在的神经保护作用.
- 缺乏关于他类药物对OIPN有效性的大规模真实世界数据.
研究的目的:
- 在现实临床环境中研究他类药物对OIPN的保护作用.
- 评估使用他类药物和在接受氧沙的癌症患者中OIPN发病率之间的关联.
主要方法:
- 一项针对接受基于氧沙的化疗的日本患者的多中心回顾性研究 (2009年4月 - 2019年12月).
- 倾向性得分匹配用于比较他类药物和非他类药物使用者之间的OIPN发病率.
- 分析包括整体癌症患者和结直肠癌 (CRC) 患者的亚组.
主要成果:
- 总的来说,2657名患者中有24.7%患有2级≥2级OIPN,在匹配后,他类药物和非他类药物组之间没有显著差异.
- 在匹配的CRC患者中 (n=510),他类药物的使用与≥2级OIPN的发生率显著降低 (19.8%对28.3%,p=0.029).
结论:
- 在接受氧沙丁治疗的一般癌症患者群体中,他类药物似乎没有提供对OIPN的显著保护.
- 有证据表明,他类药物可能为患有OIPN的结直肠癌患者提供神经保护性益处.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Peripheral Artery Disease IV: Nursing Management
350
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
350
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
197
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
197
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
256
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
256
01:27Peripheral Artery Disease III: Interprofessional Care
245
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
245